Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
Pliant Therapeutics has slammed the brakes on enrollment and dosing in a mid-stage study of its lung disease ...
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...
Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed ...
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...
The genetic disorder cystic fibrosis is unique because it can cause both breathing and digestive problems. Some 40,000 people ...
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback